Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiotherapy, Intensity-Modulated | 9 | 2023 | 794 | 2.070 |
Why?
|
Oropharyngeal Neoplasms | 8 | 2023 | 492 | 1.610 |
Why?
|
Head and Neck Neoplasms | 13 | 2023 | 2929 | 1.380 |
Why?
|
Nasopharyngeal Neoplasms | 4 | 2021 | 289 | 1.230 |
Why?
|
Radiation Oncology | 3 | 2023 | 571 | 1.160 |
Why?
|
Paranasal Sinus Neoplasms | 8 | 2016 | 243 | 1.040 |
Why?
|
Carcinoma, Adenoid Cystic | 4 | 2016 | 262 | 0.970 |
Why?
|
Skull Base | 2 | 2016 | 294 | 0.780 |
Why?
|
Relative Biological Effectiveness | 2 | 2021 | 313 | 0.760 |
Why?
|
Carcinoma, Squamous Cell | 10 | 2023 | 4049 | 0.720 |
Why?
|
Radiotherapy Dosage | 13 | 2023 | 2911 | 0.710 |
Why?
|
Diagnostic Techniques, Ophthalmological | 3 | 2006 | 252 | 0.620 |
Why?
|
Lymphoma, Extranodal NK-T-Cell | 1 | 2019 | 53 | 0.620 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 5 | 2021 | 1667 | 0.610 |
Why?
|
Skull Base Neoplasms | 3 | 2012 | 280 | 0.590 |
Why?
|
Visual Perception | 3 | 2015 | 1392 | 0.580 |
Why?
|
Nose Neoplasms | 3 | 2016 | 250 | 0.550 |
Why?
|
Radiotherapy | 4 | 2018 | 1497 | 0.540 |
Why?
|
Monte Carlo Method | 1 | 2021 | 1250 | 0.500 |
Why?
|
Papillomavirus Infections | 6 | 2023 | 1639 | 0.450 |
Why?
|
Macula Lutea | 2 | 2006 | 180 | 0.440 |
Why?
|
Carcinoma | 5 | 2021 | 2324 | 0.440 |
Why?
|
Temporal Lobe | 1 | 2021 | 1716 | 0.420 |
Why?
|
Osteoradionecrosis | 1 | 2012 | 51 | 0.410 |
Why?
|
Touch | 1 | 2015 | 313 | 0.410 |
Why?
|
Tomography, Optical Coherence | 4 | 2006 | 2937 | 0.390 |
Why?
|
Sphenoid Sinus | 2 | 2009 | 101 | 0.380 |
Why?
|
Neuroectodermal Tumors, Primitive | 1 | 2012 | 136 | 0.380 |
Why?
|
Neoplasm Metastasis | 5 | 2019 | 4891 | 0.380 |
Why?
|
Cutaneous Fistula | 1 | 2012 | 79 | 0.380 |
Why?
|
Paranasal Sinus Diseases | 1 | 2012 | 121 | 0.370 |
Why?
|
Somatosensory Cortex | 1 | 2015 | 506 | 0.360 |
Why?
|
Fistula | 1 | 2012 | 213 | 0.350 |
Why?
|
Parietal Lobe | 1 | 2015 | 859 | 0.330 |
Why?
|
Deglutition Disorders | 2 | 2013 | 640 | 0.320 |
Why?
|
Cerebellar Neoplasms | 1 | 2012 | 588 | 0.290 |
Why?
|
Retina | 3 | 2013 | 2660 | 0.280 |
Why?
|
Medulloblastoma | 1 | 2012 | 679 | 0.280 |
Why?
|
Disease-Free Survival | 8 | 2017 | 6850 | 0.270 |
Why?
|
Enteral Nutrition | 1 | 2013 | 802 | 0.270 |
Why?
|
Papillomaviridae | 6 | 2022 | 1139 | 0.270 |
Why?
|
Canthaxanthin | 1 | 2006 | 3 | 0.270 |
Why?
|
Pyrroles | 1 | 2012 | 1121 | 0.250 |
Why?
|
Angiogenesis Inhibitors | 2 | 2012 | 2057 | 0.240 |
Why?
|
Human Body | 1 | 2004 | 36 | 0.240 |
Why?
|
Extremities | 1 | 2010 | 869 | 0.230 |
Why?
|
Neuroma, Acoustic | 2 | 2005 | 456 | 0.230 |
Why?
|
Indoles | 1 | 2012 | 1834 | 0.220 |
Why?
|
Face | 1 | 2010 | 1029 | 0.220 |
Why?
|
Photic Stimulation | 1 | 2010 | 1989 | 0.220 |
Why?
|
Retinal Perforations | 1 | 2004 | 138 | 0.210 |
Why?
|
Middle Aged | 32 | 2023 | 223257 | 0.210 |
Why?
|
Visual Fields | 1 | 2010 | 1063 | 0.210 |
Why?
|
Stereotaxic Techniques | 1 | 2005 | 551 | 0.210 |
Why?
|
Urea | 1 | 2004 | 449 | 0.200 |
Why?
|
Visual Cortex | 1 | 2010 | 1081 | 0.200 |
Why?
|
Organs at Risk | 2 | 2021 | 365 | 0.190 |
Why?
|
Aged | 25 | 2023 | 171343 | 0.190 |
Why?
|
Nasolacrimal Duct | 1 | 2022 | 79 | 0.180 |
Why?
|
Brain Mapping | 2 | 2015 | 6596 | 0.180 |
Why?
|
Macular Edema | 1 | 2005 | 387 | 0.180 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2022 | 102 | 0.180 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2018 | 9404 | 0.180 |
Why?
|
Neurofibromin 2 | 3 | 2012 | 269 | 0.170 |
Why?
|
Follow-Up Studies | 9 | 2021 | 39309 | 0.170 |
Why?
|
Adult | 25 | 2021 | 223307 | 0.170 |
Why?
|
Gastrostomy | 2 | 2013 | 325 | 0.170 |
Why?
|
Radiation Injuries | 2 | 2018 | 1194 | 0.170 |
Why?
|
Male | 32 | 2023 | 364142 | 0.170 |
Why?
|
Retinal Diseases | 1 | 2006 | 709 | 0.170 |
Why?
|
Antineoplastic Agents | 2 | 2012 | 13643 | 0.160 |
Why?
|
Humans | 48 | 2023 | 766766 | 0.160 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2013 | 3552 | 0.160 |
Why?
|
Smoking | 2 | 2016 | 9077 | 0.160 |
Why?
|
Alphapapillomavirus | 1 | 2022 | 219 | 0.160 |
Why?
|
Female | 31 | 2023 | 396520 | 0.160 |
Why?
|
Kaplan-Meier Estimate | 5 | 2018 | 6512 | 0.150 |
Why?
|
Thyroid Neoplasms | 1 | 2012 | 2355 | 0.150 |
Why?
|
Radiation Tolerance | 1 | 2021 | 476 | 0.150 |
Why?
|
Radiosurgery | 2 | 2005 | 1329 | 0.150 |
Why?
|
Treatment Outcome | 11 | 2021 | 65273 | 0.150 |
Why?
|
Paranasal Sinuses | 2 | 2012 | 267 | 0.150 |
Why?
|
Antioxidants | 1 | 2006 | 1671 | 0.150 |
Why?
|
Prognosis | 9 | 2023 | 29948 | 0.140 |
Why?
|
Nasal Cavity | 3 | 2012 | 310 | 0.140 |
Why?
|
Tracheotomy | 1 | 2018 | 174 | 0.140 |
Why?
|
Retrospective Studies | 17 | 2023 | 81635 | 0.130 |
Why?
|
Karnofsky Performance Status | 1 | 2016 | 163 | 0.130 |
Why?
|
Survival Rate | 5 | 2016 | 12825 | 0.130 |
Why?
|
Neurilemmoma | 2 | 2012 | 522 | 0.130 |
Why?
|
Lymphatic Irradiation | 1 | 2016 | 115 | 0.130 |
Why?
|
Aged, 80 and over | 10 | 2017 | 59550 | 0.120 |
Why?
|
Estrogen Receptor alpha | 1 | 2019 | 581 | 0.120 |
Why?
|
Tumor Burden | 1 | 2021 | 1900 | 0.120 |
Why?
|
Neoplasm Staging | 6 | 2023 | 11218 | 0.120 |
Why?
|
Asymptomatic Diseases | 1 | 2018 | 588 | 0.120 |
Why?
|
Cranial Irradiation | 1 | 2017 | 392 | 0.120 |
Why?
|
Young Adult | 7 | 2021 | 59939 | 0.120 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2023 | 2028 | 0.120 |
Why?
|
Laryngeal Neoplasms | 1 | 2018 | 514 | 0.110 |
Why?
|
Uncertainty | 1 | 2019 | 764 | 0.110 |
Why?
|
Maxillary Sinus Neoplasms | 1 | 2014 | 38 | 0.110 |
Why?
|
Protons | 3 | 2009 | 1097 | 0.110 |
Why?
|
Physical Stimulation | 1 | 2015 | 514 | 0.110 |
Why?
|
Neoplasms | 2 | 2021 | 22350 | 0.110 |
Why?
|
Radiometry | 1 | 2018 | 812 | 0.110 |
Why?
|
Xerostomia | 1 | 2013 | 94 | 0.100 |
Why?
|
Proportional Hazards Models | 4 | 2019 | 12534 | 0.100 |
Why?
|
Neuroectodermal Tumors | 1 | 2012 | 23 | 0.100 |
Why?
|
Genes, Neoplasm | 1 | 2014 | 369 | 0.100 |
Why?
|
Ischemic Attack, Transient | 1 | 2017 | 874 | 0.100 |
Why?
|
Fingers | 1 | 2015 | 508 | 0.100 |
Why?
|
Esophageal Stenosis | 1 | 2013 | 196 | 0.100 |
Why?
|
Vision, Ocular | 1 | 2015 | 457 | 0.090 |
Why?
|
Neck Dissection | 1 | 2013 | 201 | 0.090 |
Why?
|
Postoperative Complications | 2 | 2012 | 15831 | 0.090 |
Why?
|
Nutritional Support | 1 | 2013 | 178 | 0.090 |
Why?
|
Narcotics | 1 | 2013 | 332 | 0.090 |
Why?
|
rac1 GTP-Binding Protein | 1 | 2012 | 246 | 0.090 |
Why?
|
Etoposide | 1 | 2012 | 638 | 0.090 |
Why?
|
Analysis of Variance | 2 | 2012 | 6214 | 0.090 |
Why?
|
Cranial Fossa, Anterior | 1 | 2009 | 13 | 0.090 |
Why?
|
Deglutition | 1 | 2011 | 208 | 0.090 |
Why?
|
Oropharynx | 1 | 2009 | 139 | 0.080 |
Why?
|
Wnt Proteins | 1 | 2013 | 722 | 0.080 |
Why?
|
Magnetic Resonance Imaging | 6 | 2021 | 36567 | 0.080 |
Why?
|
Constriction, Pathologic | 1 | 2011 | 1103 | 0.070 |
Why?
|
Eye Neoplasms | 1 | 2010 | 305 | 0.070 |
Why?
|
Genes, Neurofibromatosis 1 | 1 | 2007 | 75 | 0.070 |
Why?
|
Lacrimal Apparatus | 1 | 2010 | 224 | 0.070 |
Why?
|
Models, Statistical | 2 | 2019 | 5091 | 0.070 |
Why?
|
Neuroglia | 1 | 2013 | 960 | 0.070 |
Why?
|
Gene Expression | 1 | 2019 | 7585 | 0.070 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2012 | 1787 | 0.070 |
Why?
|
Neutrons | 1 | 2006 | 78 | 0.070 |
Why?
|
Cranial Fossa, Posterior | 1 | 2006 | 134 | 0.060 |
Why?
|
Cisplatin | 1 | 2012 | 1655 | 0.060 |
Why?
|
Cavernous Sinus | 1 | 2006 | 121 | 0.060 |
Why?
|
Survival Analysis | 3 | 2014 | 10100 | 0.060 |
Why?
|
Neoplasm Invasiveness | 2 | 2014 | 3609 | 0.060 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2009 | 343 | 0.060 |
Why?
|
Body Weights and Measures | 1 | 2006 | 208 | 0.060 |
Why?
|
Time Factors | 4 | 2017 | 40149 | 0.060 |
Why?
|
Triamcinolone Acetonide | 1 | 2005 | 105 | 0.060 |
Why?
|
Peroxides | 1 | 2004 | 76 | 0.060 |
Why?
|
Risk Factors | 5 | 2017 | 74881 | 0.060 |
Why?
|
Neovascularization, Pathologic | 2 | 2012 | 2631 | 0.060 |
Why?
|
Adolescent | 5 | 2018 | 88904 | 0.060 |
Why?
|
Regression Analysis | 1 | 2013 | 6329 | 0.060 |
Why?
|
Pattern Recognition, Visual | 1 | 2010 | 820 | 0.060 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2015 | 8926 | 0.060 |
Why?
|
Forecasting | 1 | 2013 | 2936 | 0.050 |
Why?
|
Quinazolines | 1 | 2010 | 1367 | 0.050 |
Why?
|
Reaction Time | 1 | 2010 | 2085 | 0.050 |
Why?
|
Sarcoma | 2 | 2012 | 1802 | 0.050 |
Why?
|
Oxygen | 1 | 2015 | 4251 | 0.050 |
Why?
|
Cranial Nerves | 1 | 2003 | 97 | 0.050 |
Why?
|
Carbon | 1 | 2006 | 673 | 0.050 |
Why?
|
Combined Modality Therapy | 5 | 2018 | 8540 | 0.050 |
Why?
|
Residence Characteristics | 1 | 2013 | 2116 | 0.050 |
Why?
|
Photons | 1 | 2006 | 588 | 0.050 |
Why?
|
Palliative Care | 1 | 2018 | 3640 | 0.050 |
Why?
|
Cytoskeleton | 1 | 2007 | 1179 | 0.050 |
Why?
|
Vitrectomy | 1 | 2005 | 392 | 0.050 |
Why?
|
Neoplasm Proteins | 1 | 2014 | 3601 | 0.050 |
Why?
|
Piperidines | 1 | 2010 | 1663 | 0.050 |
Why?
|
Cohort Studies | 3 | 2014 | 41710 | 0.050 |
Why?
|
Gene Silencing | 1 | 2007 | 1504 | 0.050 |
Why?
|
Multivariate Analysis | 2 | 2017 | 12064 | 0.050 |
Why?
|
Weight Loss | 1 | 2013 | 2712 | 0.050 |
Why?
|
Eye Diseases | 1 | 2006 | 660 | 0.050 |
Why?
|
Salvage Therapy | 1 | 2006 | 1274 | 0.040 |
Why?
|
Brain Neoplasms | 2 | 2012 | 9101 | 0.040 |
Why?
|
Nerve Tissue Proteins | 1 | 2012 | 4400 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2010 | 3511 | 0.040 |
Why?
|
Reference Values | 1 | 2006 | 4913 | 0.040 |
Why?
|
Normal Distribution | 1 | 2019 | 267 | 0.040 |
Why?
|
Drug Combinations | 1 | 2004 | 2085 | 0.040 |
Why?
|
Functional Laterality | 1 | 2004 | 2243 | 0.040 |
Why?
|
Sex Factors | 1 | 2012 | 10619 | 0.040 |
Why?
|
Brain | 1 | 2004 | 27159 | 0.040 |
Why?
|
Neurofibromatosis 2 | 2 | 2012 | 387 | 0.040 |
Why?
|
Diabetic Retinopathy | 1 | 2005 | 1300 | 0.030 |
Why?
|
Glucocorticoids | 1 | 2005 | 2158 | 0.030 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2003 | 1374 | 0.030 |
Why?
|
Amygdala | 1 | 2023 | 1375 | 0.030 |
Why?
|
Image Enhancement | 1 | 2006 | 2857 | 0.030 |
Why?
|
Stroke | 1 | 2017 | 9741 | 0.030 |
Why?
|
DNA, Viral | 1 | 2022 | 2201 | 0.030 |
Why?
|
Body Mass Index | 1 | 2013 | 13050 | 0.030 |
Why?
|
Membrane Proteins | 1 | 2012 | 7868 | 0.030 |
Why?
|
Adenocarcinoma | 2 | 2009 | 6359 | 0.030 |
Why?
|
Diagnosis, Differential | 2 | 2010 | 12985 | 0.030 |
Why?
|
Mice, Nude | 2 | 2012 | 3616 | 0.030 |
Why?
|
Kinetics | 1 | 2022 | 6287 | 0.030 |
Why?
|
Probability | 1 | 2019 | 2476 | 0.030 |
Why?
|
Radiopharmaceuticals | 1 | 2023 | 2704 | 0.030 |
Why?
|
Antibodies, Monoclonal | 1 | 2010 | 9244 | 0.030 |
Why?
|
Recovery of Function | 1 | 2003 | 2976 | 0.030 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2012 | 11872 | 0.030 |
Why?
|
Down-Regulation | 2 | 2012 | 2931 | 0.030 |
Why?
|
Eye Burns | 1 | 2013 | 64 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2014 | 2456 | 0.030 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2010 | 790 | 0.020 |
Why?
|
Thrombospondins | 1 | 2012 | 197 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2017 | 3432 | 0.020 |
Why?
|
Lasers, Solid-State | 1 | 2013 | 183 | 0.020 |
Why?
|
Permeability | 1 | 2012 | 721 | 0.020 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2014 | 904 | 0.020 |
Why?
|
Cell Growth Processes | 1 | 2010 | 381 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2005 | 15416 | 0.020 |
Why?
|
Transcription Factors | 1 | 2007 | 12150 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2012 | 2012 | 0.020 |
Why?
|
Cyclin D | 1 | 2007 | 71 | 0.020 |
Why?
|
Esthesioneuroblastoma, Olfactory | 1 | 2008 | 58 | 0.020 |
Why?
|
Signal Transduction | 3 | 2019 | 23619 | 0.020 |
Why?
|
Disease Progression | 1 | 2004 | 13640 | 0.020 |
Why?
|
Cell Compartmentation | 1 | 2007 | 383 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2023 | 6550 | 0.020 |
Why?
|
Prospective Studies | 1 | 2011 | 54871 | 0.020 |
Why?
|
Mice | 5 | 2013 | 81889 | 0.020 |
Why?
|
Blood Vessels | 1 | 2012 | 1111 | 0.020 |
Why?
|
Solubility | 1 | 2007 | 1078 | 0.020 |
Why?
|
Mutant Proteins | 1 | 2007 | 487 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2019 | 11061 | 0.020 |
Why?
|
Cyclins | 1 | 2007 | 605 | 0.020 |
Why?
|
Cell Proliferation | 2 | 2013 | 10445 | 0.010 |
Why?
|
Cell Cycle | 1 | 2013 | 2926 | 0.010 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2014 | 2881 | 0.010 |
Why?
|
Cell Polarity | 1 | 2007 | 637 | 0.010 |
Why?
|
Cell Line, Tumor | 2 | 2012 | 17088 | 0.010 |
Why?
|
Decision Making | 1 | 2018 | 3951 | 0.010 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 627 | 0.010 |
Why?
|
Endocytosis | 1 | 2007 | 951 | 0.010 |
Why?
|
Radiotherapy, Conformal | 1 | 2006 | 545 | 0.010 |
Why?
|
Cell Survival | 1 | 2013 | 5748 | 0.010 |
Why?
|
Structure-Activity Relationship | 1 | 2007 | 3053 | 0.010 |
Why?
|
Cytoskeletal Proteins | 1 | 2007 | 1325 | 0.010 |
Why?
|
Protein Transport | 1 | 2007 | 1942 | 0.010 |
Why?
|
Mice, Inbred C57BL | 2 | 2013 | 22352 | 0.010 |
Why?
|
Databases, Factual | 1 | 2017 | 8066 | 0.010 |
Why?
|
Animals | 5 | 2013 | 168930 | 0.010 |
Why?
|
Cell Adhesion | 1 | 2007 | 3093 | 0.010 |
Why?
|
Disease Models, Animal | 2 | 2013 | 18330 | 0.010 |
Why?
|
Massachusetts | 1 | 2014 | 8891 | 0.010 |
Why?
|
Protein Kinases | 1 | 2007 | 1610 | 0.010 |
Why?
|
Sirolimus | 1 | 2007 | 1540 | 0.010 |
Why?
|
Actins | 1 | 2007 | 2060 | 0.010 |
Why?
|
Genotype | 1 | 2014 | 13036 | 0.010 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2007 | 2060 | 0.010 |
Why?
|
Algorithms | 1 | 2019 | 14072 | 0.010 |
Why?
|
Cell Membrane | 1 | 2007 | 3641 | 0.010 |
Why?
|
Biopsy | 1 | 2010 | 6779 | 0.010 |
Why?
|
Fibroblasts | 1 | 2007 | 4166 | 0.010 |
Why?
|
Apoptosis | 1 | 2013 | 9513 | 0.010 |
Why?
|
Quality of Life | 1 | 2018 | 13476 | 0.010 |
Why?
|
Risk Assessment | 1 | 2017 | 24295 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2012 | 9525 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2012 | 8621 | 0.010 |
Why?
|
Protein Binding | 1 | 2007 | 9320 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2013 | 11651 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2007 | 9547 | 0.010 |
Why?
|
Cell Line | 1 | 2007 | 15563 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2007 | 5690 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2003 | 3485 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2007 | 11920 | 0.010 |
Why?
|
Mutation | 1 | 2014 | 30213 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2010 | 20708 | 0.000 |
Why?
|